Chemotherapy induced pathologic complete response in malignant pleural mesothelioma: A review and case report

Journal of Thoracic Oncology

Volumn 5, Issue 5, 2010, Pages 735-740

  Bech, Cecilia ^a   Sørensen, Jens Benn ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

CCR; Clinically complete response; Complete response; CR; Malignant pleural mesothelioma; Pathologically complete response; PCR

Indexed keywords

ASBESTOS; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; INTERLEUKIN 2; PEMETREXED;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DYSPNEA; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; MEDIASTINOSCOPY; MULTIPLE CYCLE TREATMENT; PLEURA EFFUSION; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; REVIEW; THORACOSCOPY; THORAX RADIOGRAPHY;

EID: 77951807217     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d86ea9     Document Type: Review

References (17)

1. Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for management of malignant pleural mesothelioma. Eur Respir J. In press.
2. Sorensen JB. Current concepts in chemotherapy for Malignant Pleural Mesothelioma. Clin Respir J 2008;2:74-79.
3. Sorensen JB, Frank H, Palshof T. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma. Br J Cancer 2008;99:44-50.
4. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23:6881-6889.
5. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644.
6. Hillerdal G, Sorensen JB, Sundstrom S, et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008;3:1325-1331.
7. Astoul P, Picat-Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998;83:2099-2104. (Pubitemid 28525391)
8. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 1994;74:2460-2467.
9. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax 1976;31:15-24.
10. Astoul P, Viallat JR, Laurent JC, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 1993;103: 209-213.
11. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995;76:2230-2236.
12. Krug LM, Pass HI, Rusch VW, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007-3013.
13. Rusch V W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108:1122-1128.
14. Bottomley A, Coens C, Efficace F, et al. Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 2007;25:5770-5776.
15. Fennell DA, Parmar A, Shamash J, et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005;23:184-189.
16. Gill RR, Gerbaudo VH, Sugarbaker DJ, et al. Current trends in radiologic management of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:111-120.
17. Sorensen JB, Ravn J, Loft A, et al. Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg 2008;34:1090-1096.